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Abstract To seek the cutoff value of the 28-joint disease
activity score using erythrocyte sedimentation rate (DAS28-
ESR) that is necessary to achieve remission under the new
Boolean-based criteria, we analyzed the data for 285
patients with rheumatoid arthritis registered between May
2008 and November 2009 by the Michinoku Tocilizumab
Study Group and observed for 1 year after receiving tocili-
zumab (TCZ) in real clinical practice. Remission rates under
the DAS28-ESR criteria and the Boolean criteria were
assessed every 6 months after the first TCZ dose. The
DAS28-ESR cutoff value necessary to achieve remission
under the new criteria was analyzed by receiver operating
characteristic (ROC) analysis. Data were analyzed using last
observation carried forward. After 12 months of TCZ use,
remission was achieved in 164 patients (57.5 %) by DAS28-
ESR and 71 patients (24.9 %) under the new criteria for
clinical trials. CRP levels scarcely affected remission rates,
and the difference between remission rates defined by
DAS28-ESR and by the new criteria was mainly due to
patient global assessment (PGA). Improvement of PGA
was inversely related to disease duration. ROC analysis
revealed that the DAS28-ESR cutoff value necessary to
predict remission under the new criteria for clinical trials
was 1.54, with a sensitivity of 88.7 %, specificity of 85.5 %,
positive predictive value of 67.0 %, and negative predictive
value of 95.8 %. A DAS28-ESR cutoff value of 1.54 may be
reasonable to predict achievement of remission under the
new Boolean-based criteria for clinical trials in patients
receiving TCZ.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
which fluctuates in activity during the course of the disease.
To evaluate disease activity at the time of observation, the 28-
joint disease activity score using erythrocyte sedimentation
rate (DAS28-ESR) was developed in 1995 and the cutoff
value representing remission was defined as <2.6 [1]. How-
ever, we now know that multiple joints can remain swollen or
tender at this cutoff value. Because several biologics have now
become available, achievement of complete clinical remission
has become a practical goal and the DAS28-ESR definition of
remission has now become unsuited for use in real clinical
practice. Therefore, a new definition of remission based on a
Boolean approach was approved by the American College of
Rheumatology (ACR) and the European League Against
Rheumatism (EULAR) [2]. The new criteria for clinical trials
define remission to be when tender joint count (TJC), swollen
joint count (SJC), CRP (in milligrams per deciliter), and
scores on a patient global assessment using a visual analogue
scale (PGA-VAS) (0–10-cm scale) are all ≤1. The same crite-
ria, but excluding CRP, are the new criteria for defining
remission in clinical practice.
DAS28-ESR has been used worldwide and contributes con-
siderably to the standardization of evaluation of disease activ-
ity. If the DAS28-ESR cutoff value necessary to achieve
remission under the new ACR/EULAR Boolean-based criteria
is found, it will be possible to reanalyze a lot of the accumulated
data based on DAS28-ESR. In this report, we sought this cutoff
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value on the basis of prospectively registered observational
data by the Michinoku Tocilizumab Study Group (MTSG)
which was organized to evaluate the efficacy and safety of
tocilizumab (TCZ) in real clinical practice.
Subjects and methods
Subjects
The subjects of this analysis were patients meeting the 1987
revised RA classification criteria from the ACR and who had
newly received TCZ following its marketing approval in Japan
for use in RA. A total of 285 patients in 34 institutions in the
Tohoku area were registered betweenMay 2008 andNovember
2009 by the MTSG. Their demographics and baseline charac-
teristics prior to treatment are as follows: mean age±standard
deviation (SD) was 59.6±13.1 years; male/female ratio was
21:79; mean disease duration±SD was 10.2±9.1 years; the
percentage of patients of Steinbrocker’s classes I, II, III, and
IV was 21, 57, 22, and 0 %, respectively; Steinbrocker’s stages
I, II, III, and IV was 10, 23, 29, and 38 %, respectively; mean
TJC±SD was 6.5±6.0; mean SJC±SD was 5.6±5.1; mean
ESR±SD was 50.6±32.8 mm/h; mean CRP±SD was 2.7±
2.8 mg/dl; mean PGA-VAS±SD was 5.43±2.47 cm (on a 0–
10-cm scale); and mean DAS28-ESR±SD was 5.2±1.3.
Methods
This study was not an intervention study and was approved
by the Ethics Committee of Tohoku University. The patients
had been observed for 1 year after receiving TCZ in real
clinical practice. TJC, SJC, PGA-VAS, ESR, and CRP were
assessed every 6 months after the first TCZ dose to calculate
the remission rates under the DAS28-ESR definition and
under the new 2011 ACR/EULAR Boolean-based remission
criteria. The DAS28-ESR cutoff value necessary to achieve
remission under the new criteria was analyzed by receiver
operating characteristic (ROC) analysis. Data were analyzed
using last observation carried forward.
Results
Proportions of patients achieving the criteria or each
component of the criteria
In the 285 patients, the 6-month- and 12-month TCZ contin-
uation rates were 87.4 and 81.8 %, respectively. After
6 months of TCZ use, remission was achieved by 152 patients
(53.3 %) under the DAS28-ESR definition, by 71 patients
(24.9 %) under the new criteria for clinical practice, and by 68
patients (23.9 %) under the new criteria for clinical trials
(Fig. 1). After 12 months, remission was achieved by 164
patients (57.5 %) under the DAS28-ESR definition, by 72
patients (25.3 %) under the new criteria for clinical practice,
and by 71 patients (24.9 %) under the new criteria for clinical
trials. ESR decreased from 50.6±32.8 mm/h at baseline to
14.2±21.8 after 6 months and to 13.9±21.7 after 12 months.
The mean DAS28-ESR decreased from 5.2 at baseline to 2.7
after 6 months and to 2.6 after 12months. Next, the number of


















































Fig. 1 Percentage of patients
achieving each component of
the Boolean-based remission
criteria or achieving remission
at 6 months (gray bars) or
12 months (black bars)
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remission criteria was tallied. CRP ≤1 mg/dl was achieved by
249 patients (87.4 %) at 6 months and 251 patients (88.1 %) at
12 months. TJC ≤1 was achieved by 169 patients (59.3 %) at
6 months and 179 patients (62.8 %) at 12 months. SJC ≤1 was
achieved by 190 patients (66.7 %) at 6 months and 196
patients (68.8 %) at 12 months. PGA-VAS ≤1 cm was
achieved by 80 patients (28.1 %) at 6 months and 83 patients
(29.1 %) at 12 months.
DAS28-ESR cutoff value necessary to predict achievement
of remission under the new criteria
The DAS28-ESR cutoff values necessary to achieve remis-
sion under the new criteria for clinical trials and for clinical
practice were analyzed by ROC analysis (Fig. 2). The anal-
ysis revealed that a value of 1.54 was the most accurate
cutoff value for both sets of criteria, with a sensitivity of
88.7 % (trials) and 87.5 % (practice), specificity of 85.5 %
(trials) and 85.5 % (practice), positive predictive value of
67.0 % (trials) and 67.0 % (practice), and negative predic-
tive value of 95.8 % (trials) and 95.3 % (practice). The area
under the ROC curve was 0.91 in both sets of criteria,
indicating high accuracy.
Effect of disease duration on achievement of remission
Compared to the negative predictive value, the positive
predictive value was not so high. To clarify the reason for
this, we compared the proportions of patients with DAS28-
ESR <1.54 achieving each component of the remission
criteria in the following two groups: those with disease
duration <10 years (Group 1; n059) and those with disease
duration ≥10 years (group 2; n035) (Fig. 3). CRP ≤1 mg/dl
was achieved by 59 patients (100.0 %) in group 1 and 35
patients (100.0 %) in group 2. TJC ≤1 was achieved by 58
patients (98.3 %) in group 1 and 35 patients (100.0 %) in
group 2. SJC ≤1 was achieved by 56 patients (94.9 %) in
group 1 and 34 patients (97.1 %) in group 2. In these three
components, there was no significant difference between the
two groups. On the other hand, a significant difference was
observed in PGA-VAS. PGA-VAS ≤1 cm was achieved by
47 patients (79.7 %) in group 1 but only 18 patients (51.4 %)
in group 2. Thus, PGA-VAS is the key component which
determines the remission rate, and the improvement of
PGA-VAS is inversely related to disease duration.
Discussion
In this study, our results demonstrated a high rate of DAS28-
ESR remission (53.3 %) after 6 months, which is compatible
with the results of our previous study [3]. Even under the







































Fig. 2 Receiver operating characteristic curve of DAS28-ESR <1.54 for
the ACR/EULAR Boolean-based definition of remission in clinical trials
(a) and in clinical practice (b). The arrow indicates the point where the
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Fig. 3 Percentages of patients with DAS28-ESR <1.54 achieving each
component of the Boolean-based remission criteria compared by dis-
ease duration. Gray bars disease duration <10 years, black bars disease
duration ≥10 years
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continuation rates at 6 and 12 months were also high. SJC <1
was achieved by 67–69 % of patients indicating that inflam-
mation had mostly subsided. These results are comparable to
those of the phase IIIb TAMARA study [4]. There was no
significant difference between the remission rate as deter-
mined by the new criteria for clinical trials and that for clinical
practice (P00.923). This means that, although TCZ stops
CRP gene transcription [5], the remission rate was scarcely
affected by CRP. The discrepancy between DAS28-ESR and
the new criteria was mainly due to PGA (Fig. 1).
ROC analysis revealed that the DAS28-ESR cutoff point
necessary to predict achievement of remission under the
new criteria, both for clinical trials and for clinical practice,
was DAS28-ESR <1.54 (Fig. 2). This also means that this
cutoff value is not affected by CRP. Sensitivity and speci-
ficity were reasonably high. Negative predictive value was
very high (>95 %) and the area under the ROC curve was
>0.9, indicating high accuracy. Moreover, the cutoff value is
clearly below the more stringent DAS28-ESR cutoff
point (DAS28-ESR <2.0) examined by the ACR and
the EULAR as a candidate definition of remission [2].
Therefore, DAS28-ESR <1.54 may be a reasonable
cutoff value to predict achievement of remission under
the new ACR/EULAR Boolean-based criteria for TCZ.
Of course, it is not known whether this value can be
used for other antirheumatic drugs until other drugs are
studied in the same way because TCZ strongly
improves ESR by markedly ameliorating inflammatory
anemia [6] and decreasing inflammatory molecules such
as fibrinogen [7].
A new definition of remission based on the simpli-
fied disease activity index (SDAI) was also approved by
the ACR and the EULAR [2]. However, in this study,
we could not indicate a DAS28-ESR cutoff value pre-
dicting SDAI <3.3 because the prospectively registered
observational data did not include the physician global
assessment. We would like to investigate this when we
have a chance.
In general, longer disease duration is associated with more
severe joint destruction. Understandably, joint destruction
decreases quality of life and increases the points on the Health
Assessment Questionnaire (HAQ). This increased HAQ score
is the damage-related component of the HAQ (DAM-HAQ)
of which improvement is not easy [8, 9]. At the damaged
joints, motion pain frequently remains even after treatment has
resulted in disappearance of inflammation. Therefore,
although most patients achieved TJC ≤1 and SJC ≤1,
improvement of PGA-VAS is limited in the patients
with longer disease duration (Fig. 3). This means that,
due to DAM-HAQ, criteria using PGA-VAS could be
inaccurate for evaluating disease activity in patients with
longer disease duration. One way to improve the accu-
racy of assessing remission would be to change the
cutoff value of PGA-VAS depending on the disease
duration or the degree of joint destruction such as
determined by the modified total Sharp score.
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